Search results
Results From The WOW.Com Content Network
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
Tissue-type plasminogen activator. Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease ( EC 3.4.21.68) found on endothelial cells lining the ...
Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form plasminogen. Plasmin is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting. There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator ...
It received full Food and Drug Administration approval in July. ... the first treatment doctors often consider is a clot-dissolving medicine called tPA, which can make brain bleeding worse.
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. [ 1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism. [ 2] The type of heart attack it is used in is an ST elevation myocardial infarction (STEMI). [ 3]
Third-party administrator. In the United States, a third-party administrator ( TPA) is an organization that processes insurance claims or certain aspects of employee benefit plans for a separate entity. [ 1] It is also a term used to define organizations within the insurance industry which administer other services such as underwriting and ...
Urokinase, also known as urokinase-type plasminogen activator ( uPA ), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. [ 5] Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix ...
39 589.75 g·mol −1. (verify) Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them. Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein.